Quest Magazine

MDA Study Reveals ‘Cost of Illness’ for ALS, DMD, MMD

"We now have numbers to point to," said Annie Kennedy, MDA's senior vice president of advocacy. "It's not just a back-of-the-envelope calculation anymore. It's real data."

CMD, LGMD: New Light Shed on Sugar-Coating Process

Glycosylation — "sugar-coating" — of the muscle protein alpha-dystroglycan is known to be a crucial part of muscle function.

Without sufficient glycosylation, alpha-dystroglycan doesn't stick well to other proteins, and an important linkage between muscle fibers and their surroundings is disrupted.

Stars Announced For MDA Telethon This Labor Day Weekend On ABC-TV

Safeway Shoppers ‘Make A Difference’ At the Register For MDA

Jiffy Lube Service Centers Nationwide Fight Back Against Muscle Disease This August

Trial to Evaluate the Hormone Drug Acthar in ALS

A 40-person phase 2 clinical trial to test the safety and tolerability of Questcor Pharmaceuticals’ H.P. Acthar Gel (Acthar) in people with amyotrophic lateral sclerosis (ALS) has opened at a trial site in Phoenix, Ariz.

Nationwide Children’s Podcast Explores Therapy Development for DMD

In a July 2013 podcast from Nationwide Children’s Hospital in Columbus, Ohio, longtime MDA grantee Jeffrey Chamberlain discusses recent advances in the development of gene therapy (gene transfer) and stem cell therapy (transplantation) for Duchenne muscular dystrophy (DMD), the results of which may apply to other types of muscular dy

DMD: Multicenter Trial To Test Drug that Fights Muscle Scarring, Inflammation

A phase 1b/2a clinical trial to test the safety, tolerability and pharmacokinetics of single and multiple doses of HT-100 (also called delayed-release halofuginone) in boys with Duchenne muscular dystrophy (DMD) is now open at four sites in Maryland, Missouri and Ohio, with an additional site expected to open in California.

MDA Statement RE: Sarepta Therapeutics To Submit NDA for Duchenne Muscular Dystrophy Next Year

'Sugar' Molecule Delays Disease Progression in ALS Mice

Treatment with a small molecule called trehalose was associated with slower disease progression and longer life span in mice with a disease mimicking amyotrophic lateral sclerosis (ALS), an MDA-supported research team has reported.

Trehalose is a compound composed of two glucose (sugar) molecules.